Back

Adherence to dual anti-platelet therapy after acute coronary syndrome and its impact on patient outcome

1 September 2020 (08:30 - 08:30)
Organised by:
Congress Presentation Part of: Antithrombotic Therapy Update Antiplatelet Drugs ESC Premium Access ESC Congress 2020

About the speaker

Photo
Professor Patrick Sulzgruber

Danube Private University (DPU), Krems an der Donau (Austria)

6 More presentations in this session

Presentation thumbnail
First-in-human study to assess the safety, pharmacokinetics and pharmacodynamics of BMS-986177/JNJ-70033093, a direct, reversible, small molecule Factor XIa inhibitor in healthy volunteers
Doctor V. Perera (Berlin, DE)
Abstract Slides
Presentation thumbnail
S62798, a TAFIa inhibitor, accelerates endogenous thrombolysis in a murine model of pulmonary thromboembolism
Doctor P. Sansilvestri-Morel (Suresnes, FR)
Abstract Slides
Presentation thumbnail
Favorable therapeutic index of an orally-active small-molecule antagonist of the platelet protease-activated receptor-4, BMS-986141, compared with the P2Y12 antagonist ticagrelor in cynomolgus monkeys
Doctor P. Wong (Princeton, US)
Abstract Slides
Presentation thumbnail
Orodispersible ticagrelor use in acute coronary syndrome patients: the Ticagrelor Administered as Standard Tablet or orodispersiblE foRmulation (TASTER) Study
Professor G. Parodi (Sassari, IT)
Abstract Slides
Presentation thumbnail
Benefit and risks of extended dual antiplatelet therapy beyond 1 year in high-risk patients after drug-eluting stent implantation
Doctor H. Wang (Beijing, CN)
Abstract Slides

Access the full session

Session thumbnail
Antithrombotic Therapy Update

The Event

Event poster

ESC Congress 2020

1 September 2020 08:30 CET
You may be interested in
thumbnail
Webinar
Aspirin treatment for mitigating thrombotic risk across the cardiovascular risk continuum
thumbnail
Congress Presentation
Antithrombotic therapy in diabetes
thumbnail
Congress Session
State-of-the-art antithrombotic treatment in acute coronary syndromes: a paradigm shift?

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources